New enterprise platform powered by CARAai targets faster protocol design, smarter site selection, and real-time study monitoring for sponsors and contract research organizations
CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI, a leading oncology real-world evidence and AI SaaS technology company, today unveiled Accelerated Clinical Trials (ACT), an enterprise agentic artificial intelligence (AI) platform designed to automate and inject predictive intelligence across the end-to-end clinical trial process. Launched at Summit for Clinical Ops Executives (SCOPE) 2026 in Orlando, ACT integrates real-world and proprietary data with advanced AI workflows to help sponsors and contract research organizations (CROs) shorten overall trial timelines by 10 to 20 months, significantly reduce costs, and bring therapies to market faster.
Clinical research faces increasing complexity, with challenges in patient recruitment, intricate trial endpoints, and data silos that often force sponsors to make costly midstream changes. A study from the Tufts Center for the Study of Drug Development (CSDD) found that 76% of Phase I-IV trials require amendments, and each major change can add months and cost hundreds of thousands of dollars. ACT addresses these issues by transforming clinical research operations into a fully integrated, intelligent ecosystem. By leveraging AI-driven probability forecasts, ACT empowers teams to design and operate trials with a higher likelihood of meeting enrollment goals and delivering successful outcomes.
“Trial inefficiencies come at a high cost – both financial and for patients awaiting new therapies. Sponsors don’t need another isolated tool; they need an end-to-end solution that identifies bottlenecks and guides next steps,” said Eron Kelly, Chief Executive Officer of ConcertAI. “With ACT, we deliver on the promise of agentic AI for life sciences, giving trial teams greater control and clear visibility throughout the entire study lifecycle.”
Leveraging Agentic AI as the Foundation for Clinical Trial Acceleration
Built on CARAai™, ConcertAI’s proprietary agentic AI platform, ACT deploys a suite of purpose-built assistants and agents that leverage advanced reasoning models to automate critical trial activities such as literature reviews, protocol design, competitive trial analysis, feasibility assessments, site selection, and patient matching. Based on the design foundation for ACT, the company was recently recognized in the top AI Clinical Trial Automation Solutions for 2026 by Frost & Sullivan.
According to the “Frost Radar: Artificial Intelligence-Enabled Clinical Trials, 2026” report, “ConcertAI is one of the key competitors in utilizing generative and agentic AI and proprietary RWD to transform clinical trial operations by enabling trial sponsors and research networks to expedite patient screening, optimize site selection, and automate end-to-end research workflows. The CARAai multimodal platform stands out for its applied integration […], producing precise patient-to-trial matches for oncology trials while also addressing protocol design challenges that used to be solely based on EMR drivers.”
ACT’s intelligent agents draw on both real-world and proprietary data, enabling trial teams to accelerate complex tasks, make data-driven decisions faster, and achieve greater accuracy throughout the clinical trial lifecycle. For development teams, ACT’s design and writing tools can cut study design timelines by up to 50 percent and reduce costly amendments by approximately 50 percent through AI-driven feasibility validation. Operationally, the platform streamlines site selection, activation, and recruitment, reducing timelines by 25-50 percent through automated validation strategies. CARAai also supports connectors to sources such as PubMed and ClinicalTrials.gov, while integrations with common trial platforms ensure seamless adoption within existing workflows.
ConcertAI will showcase ACT at booth #315 during SCOPE from February 2–5, 2026.
About ConcertAI
ConcertAI provides purpose-built, enterprise artificial intelligence and real-world data solutions for life sciences and healthcare organizations, turning complex health data into actionable insights that advance research and care. Its proprietary Precision Suite SaaS solution and CARAai platform deliver agentic AI capabilities designed for healthcare’s biggest challenges and are trained specifically for life sciences use cases like translational medicine, clinical development, clinical trials and commercial acceleration. Working with 75% of the top 30 life sciences organizations, more than 2,000 healthcare providers and medical societies, and a broad network of industry partners, ConcertAI has built the market’s most comprehensive clinicogenomic datasets to fuel drug development, trial acceleration, and advance clinical care. Through our data, AI technology, partnerships, and expertise, we empower oncologists and radiologists with real-time clinical insights at the point of care for better patient outcomes, and equip researchers with solutions to accelerate life-changing therapies to patients. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, and Tokyo. Learn more at concertai.com.
Contacts
Media Contact:
Jessika Parry
[email protected]
419-266-4016
